2012-11-20 09:06:37 - OSI Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report - a new company profile report on companiesandmarkets.com

OSI Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company´s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

- Detailed information on OSI Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting OSI Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of OSI Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for OSI Pharmaceuticals, Inc.
-

 

 

Intelligence on OSI Pharmaceuticals, Inc.nv´s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about OSI Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

OSI Pharmaceuticals (OSI) is a biotechnology company focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. OSI primarily operates in the US. It is headquartered in Melville, New York and employs 535 people. The company recorded revenues of $428.1 million during the financial year (FY) ended December 2009, an increase of 12.8% over FY2008. The increase in revenues was primarily due to the higher sales of Tarceva. The operating profit of the company was $152.7 million during FY2009, an increase of 14.6% over FY2008. The net profit of the company was $75.9 million in FY2009, as compared to the net profit of $441.6 million in FY2008.
Reasons to Purchase:

- Gain understanding of OSI Pharmaceuticals, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess OSI Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers´ businesses better
- Stay up to date on OSI Pharmaceuticals, Inc.´s business structure, strategy and prospects

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Company Profile Reports www.companiesandmarkets.com/Market/All/Company-Profile?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.